| Birth Date: | 27 September 1936 |
| Birth Place: | Madrid, Spain |
| Citizenship: | American |
| Fields: | Biochemistry, pharmacology, medicine |
| Workplaces: | UC San Diego |
| Education: | Washington University School of Medicine, M.D. 1962 |
| Known For: | Invention of affinity chromatography |
| Awards: | Wolf Prize in Medicine |
Pedro Cuatrecasas (born 27 September 1936) is an American biochemist and an adjunct professor of Pharmacology & Medicine at the University of California San Diego.[1]
Pedro Cuatrecasas was born in 1936 in Madrid, Spain.[2] He completed his A.B. from Washington University in St. Louis in 1958. He completed his M.D. from Washington University School of Medicine in 1962.
Pedro Cuatrecasas is known for the invention and development of affinity chromatography, a process utilized within the Aethlon HemopurifierTM. He was involved in the discovery, development and marketing registration of more than forty medicines. Some of those medicines include: zidovudine (AZT, AIDS), acyclovir (Zovirax, anti-herpes), permethrin (Rid, head and body lice), bupropion (Wellbutrin, antidepressant), colfosceril palmitate (Exosurf, infant acute respiratory distress), remifentanil (Ultiva, analgesic/anesthetic), sumatriptan (Imigran, migraine), salmeterol (Serement, asthma), tacrine (Cognex, Alzheimers), gabapentin (Neurontin, epilepsy and neuropathic pain), troglitazone (Rezulin, diabetes), and atorvastatin (Lipitor, cholesterol lowering).
In 1987 Pedro Cuatrecasas won the Wolf Prize in Medicine in 1987 along with Meir Wilchek "for the invention and development of affinity chromatography and its applications to biomedical sciences."[3]